Abstract:Zolmitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine. There are few reports regarding the in vitro metabolism of zolmitriptan. Previous studies indicated zolmitriptan was metabolized via CYP1A2 in human hepatic microsomes. In order to study the enzyme kinetics and drug interaction, the metabolism of zolmitriptan and possible drug-drug interactions were investigated in rat hepatic microsomes induced with different inducers. An active metabolite, N-demethylzolmitriptan, was detected and another minor, inactive metabolite that was reported in human hepatic microsomes was not detected in this study. The enzyme kinetics for the formation of N-demethylzolmitriptan from zolmitriptan in rat liver microsomes pretreated with BNF were 96+/-22 microM (K(m)), 11+/-3 pmol min(-1)mg protein(-1) (V(max)), and 0.12+/-0.02 microl min(-1)mg protein(-1) (CL(int)). Fluvoxamine and diphenytriazol inhibited zolmitriptan N-demethylase activity catalyzed by CYP1A2 (K(i)=3.8+/-0.3 and 3.2+/-0.1 microM, respectively). Diazepam and propranolol elicited a slight inhibitory effect on the metabolism of zolmitriptan (K(i)=70+/-11 and 90+/-18 microM, respectively). Cimetidine and moclobemide produced no significant effect on the metabolism of zolmitriptan. Fluvoxamine yielded a k(inactivation) value of 0.16 min(-1), and K(i) of 57 microM. The results suggest that rat hepatic microsomes are a reasonable model to study the metabolism of zolmitriptan, although there is a difference in the amount of minor, inactive metabolites between human hepatic microsomes and rat liver microsomes. The results of the inhibition experiments provided information for the interactions between zolmitriptan and drugs co-administrated in clinic, and it is helpful to explain the drug-drug interactions of clinical relevance on enzyme level. This study aso demonstrated that fluvoxamine may be a mechanism-based inactivator of CYP1A2.

[Metabolism-Based Interaction of Diphenytriazol and Flavone Compounds].

In Vitro Metabolic Interaction Between Diphenytriazol and Steroid Hormone Drugs

Induction of Diphenytriazol on Cytochrome CYP1A.

Interaction Between Ipriflavone and Other Drugs in Metabolism in Vitro

Inhibitive Effect of Diphenytriazol on Rat Cytochrome P450 Enzyme in Vitro

Drug Interaction of Nifedipine with Ginkgo Flavones in vitro

In Vitro Metabolism and Inductive or Inhibitive Effect of DL111 on Rat Cytochrome P4501A Enzyme.

[Ginkgo Flavones in in Vitro Metabolism and Its Clinical Application].

[Research Progress on Interactions Between Luteolin (glucosides) and Drug-Metabolizing Enzyme].

[Glucuronidation and in Vitro Interaction of Ginkgo Flavonoids with Other Drugs].

In Vitro Metabolism of Zolmitriptan in Rat Cytochromes Induced with Β-Naphthoflavone and the Interaction Between Six Drugs and Zolmitriptan

[Research progress on drug metabolism of flavanoids].

Drug Interaction Study of Flavonoids Toward CYP3A4 and Their Quantitative Structure Activity Relationship (QSAR) Analysis for Predicting Potential Effects.

Metabolism of flavonoids in human: a comprehensive review.

Effects of Diosmetin on Nine Cytochrome P450 Isoforms, UGTs and Three Drug Transporters in Vitro

Investigating the interactions of flavonoids with human OATP2B1: inhibition assay, IC50 determination, and structure-activity relationship analysis

Potential Metabolism Determinants and Drug-Drug Interactions of a Natural Flavanone Bavachinin

Investigation of the Interactions Between Flavonoids and Human Organic Anion Transporting Polypeptide 1B1 Using Fluorescent Substrate and 3D-QSAR Analysis.

Mechanism of CYP2C9 Inhibition by Flavones and Flavonols

Inhibitory Effects of Quercetin and Its Main Methyl, Sulfate, and Glucuronic Acid Conjugates on Cytochrome P450 Enzymes, and on OATP, BCRP and MRP2 Transporters

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid